Spots Global Cancer Trial Database for ifct
Every month we try and update this database with for ifct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | NCT02727335 | Non-small Cell ... Anaplastic Lymp... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| ENCOrafenib With Binimetinib in bRAF NSCLC | NCT04526782 | Non Small Cell ... BRAF V600E | Encorafenib 75 ... Binimetinib 15 ... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | NCT04233021 | Non Small Cell ... Leptomeningeal ... Brain Metastase... EGFR Activating... | Osimertinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | NCT04621188 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | NCT01631136 | Advanced Non Sm... | Cisplatin Pemetrexed Cisplatin Gemcitabine | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib | NCT03727477 | Non-small Cell ... ALK Gene Rearra... ROS-1 Gene Rear... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| Paclitaxel-bevacizumab in Advanced Lung Cancer | NCT01763671 | Non-squamous No... | Docetaxel Paclitaxel Bevacizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | NCT02727335 | Non-small Cell ... Anaplastic Lymp... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) | NCT06053099 | Non Small Cell ... EGFR Activating... EGFR DEL19 EGFR L858R | Plasma ctDNA FFPE blocks | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Chemotherapy for Lung Cancer in HIV-positive Patients | NCT01296113 | Non-small Cell ... Hiv-positive | Chemotherapy | 18 Years - 75 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | NCT05154344 | MET Alterations Non Small Cell ... METex14 Mutatio... | Capmatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | NCT05154344 | MET Alterations Non Small Cell ... METex14 Mutatio... | Capmatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | NCT03977194 | Non Small Cell ... | Carboplatin Paclitaxel Atezolizumab | 70 Years - 89 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program | NCT02933346 | Non-small Cell ... Nivolumab Long-term Adver... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| French National Observatory of Patients With Thymic Epithelial Tumor | NCT02724696 | Thymic Epitheli... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | NCT05273047 | Nsclc KRAS P.G12C | 18 Years - 90 Years | Intergroupe Francophone de Cancerologie Thoracique | ||
| Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. | NCT01705184 | Non-small Cell ... Nonsquamous Non... | Cisplatin Bevacizumab Pemetrexed | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer | NCT03030131 | Carcinoma, Non-... | Durvalumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Her2-positive Lung Cancer Treated With Dedicated Drug | NCT03845270 | Non Small Cell ... Non Small Cell ... HER2 Gene Mutat... | pertuzumab + tr... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| French National Observatory of Patients With Thymic Epithelial Tumor | NCT02724696 | Thymic Epitheli... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer | NCT01817192 | Non-Small Cell ... | Adjuvant Chemot... Radiographic su... 14-Gene Prognos... | 18 Years - | Encore Clinical | |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | NCT04111705 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC | NCT04920981 | Small Cell Lung... | atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | NCT01631136 | Advanced Non Sm... | Cisplatin Pemetrexed Cisplatin Gemcitabine | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | NCT03591731 | Neuroendocrine ... | Nivolumab Ipilimumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Immunotherapy in Patient With Poor General Condition | NCT04108026 | Non-small Cell ... | Durvalumab | 18 Years - 75 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | NCT03469960 | Non-Small Cell ... | Ipilimumab Nivolumab | 18 Years - 75 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | NCT05200481 | Non Small Cell ... ALK Gene Mutati... | Brigatinib 180 ... Carboplatin Pemetrexed | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
